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Background
In the United States, Prostate cancer is the most com-
mon tumour in men, with an expected 192.280 new
cases and 27.360 deaths estimated in 2009 [1]. About
81% of patients with prostate cancer are over 65 years
of age. Prostate cancer is a biologically heterogeneous
neoplasm in which, especially in the elderly, some forms
remain silent and with risk of disease-treatment. More-
over, this population may not receive optimal therapies
for their disease, if decisions are based only on their
chronological age. Health status, more than age, is a
major factor affecting individual life expectancy. Comor-
bidity is the key predictor of health status, and should
weigh more on the treatment decision than age alone.
Other important parameters to consider in the elderly
are the degree of dependence in activities of daily living,
the nutritional status and the presence or not of a geria-
tric syndrome. The androgen-deprivation therapy (ADT)
has become an integral piece of the armamentarium for
treating prostate cancer in neoadjuvant, adjuvant and
palliative therapy [2]. The impact on health-related qual-
ity of life (HRQOL) following ADT induction has gained
significant clinical attention. Several series documented
an association between ADT and declining HRQOL [3].
Treatment of hormone refractory metastatic prostate
cancer with Docetaxel 75 mg/m2 every 3 weeks (3W) in
combination with daily prednisone has been shown to
prolong survival and to have the same efficacy in healthy
elderly as in younger patients [4].
Conclusions
Geriatric assessment in elderly patients with prostate
cancer is crucial. Each treatment has to be adapted to
health status.
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